Naveed Sattar co-led an examination of the cardiovascular effects of Tirzepatide
Published: 21 March 2022
Naveed Sattar co-led an examination of the cardiovascular effects of Tirzepatide. This work shows clear cardiovascular safety and a hint at future benefit.
Naveed Sattar co-led an examination of the cardiovascular effects of Tirzepatide, relative to comparators in phase 3 studies, published in Nature Medicine. This work shows clear cardiovascular safety and a hint at future benefit, something being tested further in SURPASS CVOT (12, 500 patients recruited); Naveed is on the trial executive committee. Tirzepatide is likely to be the first dual GLP-1-GIP agonist to reach market and many are keen to see its fuller clinical impact given its ability to help patients consistently lose weight by more than 10kg in recent trials.
Naveed also co-led work, published in Diabetes Care, on the life years gained free from cardiovascular outcomes with use of semaglutide, a GLP-1RA drug attracting similar interest.
First published: 21 March 2022